Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN054
- Development stage
- Preclinical
- Lead developer
- Suzhou Alphamab
01
Overview
KN054 is an innovative biologic drug candidate being developed by Suzhou Alphamab Co., Ltd. for the treatment of hematological (blood) diseases. As an early-stage pipeline asset, specific details regarding its molecular target, mechanism of action, and clinical phase have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on KN054.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN054.